The Montreal Heart Institute is being sued for $45-million by a pharmaceutical company.
Cerenis Therapeutics Holdings had paid the Institute 17-million dollars to conduct a study of the effectiveness of a new drug for atherosclerosis.
More than 500 patients in several countries underwent heart exams by ultrasound before and after being treated with the drug.
In its lawsuit, Cerenis claims the Heart Institute was too selective in its culling of ultrasound images and, as a result the study was compromised and will have to be redone.
The Institute says it will contest the company's allegations in court.